Safety Profile of Nifurtimox and Treatment Interruption for Chronic Chagas Disease in Colombian Adults

Nifurtimox (NFX) is one of the approved drugs used to treat Chagas disease. Safety profile studies and models on risk factors for treatment interruption in adults are scarce in Latin America. This study evaluated retrospectively the medical records of adult Chagas disease patients treated with NFX between 2007 and 2012 in Bogotá, Colombia. An accelerated failure time model was used, and associations were expressed as time ratio (TR). In total, 76 adult patients with NFX were included: 60 (79.0%) completed 60 days of treatment, 61 (80.3%) presented adverse drug reactions (ADRs), and 16 (21.0%) required treatment interruption. The predominant symptoms were epigastric pain (23.7%), nauseas (18.4%), sleep disturbances (18.4%), loss of appetite (17.1%), and temporary loss of memory (15.2%). ADRs were classified as mild (64.5%), moderate (30.4%), and severe (5.1%). Time of treatment was significantly longer when presenting ≤ 3 ADRs (TR: 1.78; 95% CI: 1.04–3.03), presence of non-severe ADRs (TR: 6.52; 95% CI: 3.24–13.1), doses of NFX ≤ 8 mg/kg/day (TR: 1.78; 95% CI: 0.90–3.49), and age < 48 years (TR: 1.57; 95% CI: 0.90–2.74). Treatment with NFX in adults caused a high frequency of ADRs, but most of the cases were mild and did not require treatment interruption. Severity and number of ADRs were the main predictors for treatment interruption.

[1]  G. Guyatt,et al.  Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection. , 2014, The Cochrane database of systematic reviews.

[2]  Z. Cucunubá,et al.  Follow-up of an Asymptomatic Chagas Disease Population of Children after Treatment with Nifurtimox (Lampit) in a Sylvatic Endemic Transmission Area of Colombia , 2015, PLoS neglected tropical diseases.

[3]  R. López-Vélez,et al.  Nifurtimox therapy for Chagas disease does not cause hypersensitivity reactions in patients with such previous adverse reactions during benznidazole treatment. , 2013, Acta Tropica.

[4]  Mauro M. Teixeira,et al.  Diagnosis and management of Chagas disease and cardiomyopathy , 2012, Nature Reviews Cardiology.

[5]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[6]  Haitao Chu,et al.  Parametric survival analysis and taxonomy of hazard functions for the generalized gamma distribution , 2007, Statistics in medicine.

[7]  C. Combescure,et al.  Tolerance and safety of nifurtimox in patients with chronic chagas disease. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  M. Ingaramo,et al.  Evolutive behavior towards cardiomyopathy of treated (nifurtimox or benznidazole) and untreated chronic chagasic patients. , 2000, Revista do Instituto de Medicina Tropical de Sao Paulo.

[9]  Michael P Barrett,et al.  Chemotherapy of trypanosomiases and leishmaniasis. , 2005, Trends in parasitology.

[10]  Chagas disease in Latin America: an epidemiological update based on 2010 estimates. , 2015, Releve epidemiologique hebdomadaire.

[11]  E. Chatelain,et al.  Serological and parasitological response in chronic Chagas patients 3 years after nifurtimox treatment , 2013, BMC Infectious Diseases.

[12]  G. M. Sperandio da Silva,et al.  A Clinical Adverse Drug Reaction Prediction Model for Patients with Chagas Disease Treated with Benznidazole , 2014, Antimicrobial Agents and Chemotherapy.

[13]  Jelena Savović,et al.  Methods for Causality Assessment of Adverse Drug Reactions , 2008, Drug safety.

[14]  Francisco Rogerlândio Martins-Melo,et al.  Multiple causes of death related to Chagas' disease in Brazil, 1999 to 2007. , 2012, Revista da Sociedade Brasileira de Medicina Tropical.

[15]  D. Kleinbaum,et al.  Survival Analysis: A Self-Learning Text. , 1996 .

[16]  A. Rassi,et al.  Chagas' Heart Disease , 2000, Clinical cardiology.

[17]  J. Altcheh,et al.  [Congenital Chagas disease: experience in the Hospital de Niños, Ricardo Gutiérrez, Buenos Aires, Argentina]. , 2005, Revista da Sociedade Brasileira de Medicina Tropical.

[18]  R. Mahajan,et al.  Patterns of ADRs and Risk Factors Involved: Study In Cardiology Unit Of An Indian Tertiary Care Center , 2009 .

[19]  F. Koberle.  [Chagas' heart disease]. , 1958, Hospital.

[20]  S. Hughes.  Prescribing for the elderly patient: why do we need to exercise caution? , 1998, British journal of clinical pharmacology.

[21]  D. Greenblatt,et al.  A method for estimating the probability of adverse drug reactions , 1981, Clinical pharmacology and therapeutics.

[22]  D. Fabbro,et al.  Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution. , 2007, Revista da Sociedade Brasileira de Medicina Tropical.

[23]  A. Ribeiro,et al.  An update on the management of Chagas cardiomyopathy , 2007, Expert review of anti-infective therapy.

[24]  D. Fabbro,et al.  [Longitudinal study and specific chemotherapy in children with chronic Chagas' disease, residing in a low endemicity area of Argentina]. , 2004, Revista da Sociedade Brasileira de Medicina Tropical.

[25]  G. M. Sperandio da Silva,et al.  Safety of benznidazole use in the treatment of chronic Chagas' disease. , 2012, The Journal of antimicrobial chemotherapy.

[26]  N. Balakrishnan,et al.  Generalized gamma frailty model , 2006, Statistics in medicine.

[27]  H. Coelho,et al.  [Ceará State Pharmacovigilance System: a year of experience]. , 1999, Cadernos de saude publica.

[28]  Su-Yoen Park,et al.  Factors Associated With the Time to Next Attack in Neuromyelitis Optica: Accelerated Failure Time Models With Random Effects , 2013, PloS one.

[29]  Robert H Gilman,et al.  Evaluation and treatment of chagas disease in the United States: a systematic review. , 2007, JAMA.

[30]  Lee-Jen Wei,et al.  The accelerated failure time model: a useful alternative to the Cox regression model in survival analysis. , 1992, Statistics in medicine.

[31]  J. R. Cançado.  Long term evaluation of etiological treatment of chagas disease with benznidazole. , 2002, Revista do Instituto de Medicina Tropical de Sao Paulo.

[32]  I. Lobo,et al.  Etiological drug treatment of human infection by Trypanosoma cruzi. , 1996, Revista do Instituto de Medicina Tropical de Sao Paulo.

[33]  J. Coura,et al.  [Comparative controlled study on the use of benznidazole, nifurtimox and placebo, in the chronic form of Chagas' disease, in a field area with interrupted transmission. I. Preliminary evaluation]. , 1997, Revista da Sociedade Brasileira de Medicina Tropical.

[34]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[35]  J. Gascón,et al.  Tolerance of Benznidazole in Treatment of Chagas' Disease in Adults , 2010, Antimicrobial Agents and Chemotherapy.